Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Doxil doxorubicin: Phase II data

In a Phase II trial in 30 evaluable patients aged 60 years

Read the full 123 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE